These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8610466)

  • 21. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.
    Klasse PJ; McKeating JA
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):595-604. PubMed ID: 8369164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
    Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
    Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    Chiou SH; Freed EO; Panganiban AT; Kenealy WR
    AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody.
    Krugner-Higby L; Goff D; Edwards T; Iyer N; Neufeld J; Kute T; Morris-Natschke S; Ishaq K; Piantadosi C; Kucera LS
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):705-12. PubMed ID: 7576930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.
    Savarino A; Bensi T; Chiocchetti A; Bottarel F; Mesturini R; Ferrero E; Calosso L; Deaglio S; Ortolan E; Buttò S; Cafaro A; Katada T; Ensoli B; Malavasi F; Dianzani U
    FASEB J; 2003 Mar; 17(3):461-3. PubMed ID: 12551845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human immunodeficiency virus infection of CD4+ cells by CD4-free glycopeptides from monocytic U937 cells.
    Mbemba E; Carré V; Atemezem A; Saffar L; Gluckman JC; Gattegno L
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):47-53. PubMed ID: 8825618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the anti-HIV properties of oxihumate.
    van Rensburg CE; Dekker J; Weis R; Smith TL; Janse van Rensburg E; Schneider J
    Chemotherapy; 2002 Jul; 48(3):138-43. PubMed ID: 12138330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
    Potts BJ; Field KG; Wu Y; Posner M; Cavacini L; White-Scharf M
    Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.
    Wyatt JR; Vickers TA; Roberson JL; Buckheit RW; Klimkait T; DeBaets E; Davis PW; Rayner B; Imbach JL; Ecker DJ
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1356-60. PubMed ID: 7906414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight.
    Cushman M; Wang PL; Chang SH; Wild C; De Clercq E; Schols D; Goldman ME; Bowen JA
    J Med Chem; 1991 Jan; 34(1):329-37. PubMed ID: 1704065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human immunodeficiency virus type 1 replication and cytopathicity by synthetic soluble catecholamine melanins in vitro.
    Montefiori DC; Modliszewski A; Shaff DI; Zhou J
    Biochem Biophys Res Commun; 1990 Apr; 168(1):200-5. PubMed ID: 2327999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
    In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical review of humic acid as an antiviral: Leadup to translational applications in clinical humeomics.
    Socol DC
    Front Pharmacol; 2022; 13():1018904. PubMed ID: 36712657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of Organic Compounds, Fulvic Acid, Humic Acid, and Humin in Peat and Sapropel Alkaline Extracts.
    Jarukas L; Ivanauskas L; Kasparaviciene G; Baranauskaite J; Marksa M; Bernatoniene J
    Molecules; 2021 May; 26(10):. PubMed ID: 34069989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comprehensive Toxicological Assessment of Fulvic Acid.
    Dai C; Xiao X; Yuan Y; Sharma G; Tang S
    Evid Based Complement Alternat Med; 2020; 2020():8899244. PubMed ID: 33381216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral activity of natural humic substances and shilajit materials against HIV-1: Relation to structure.
    Zhernov YV; Konstantinov AI; Zherebker A; Nikolaev E; Orlov A; Savinykh MI; Kornilaeva GV; Karamov EV; Perminova IV
    Environ Res; 2021 Feb; 193():110312. PubMed ID: 33065073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective.
    Bruccoleri A
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):4-12. PubMed ID: 22938539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.